RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke' (PRECIOUS).

assistant: **Concept**

Every year, 1.3 million Europeans have a stroke and one million ultimately die of stroke. One third of stroke patients remain dependent on the help of others. The annual costs for stroke care in Europe are estimated at € 64.1 billion. Stroke incidence increases almost exponentially with age, and the personal, societal, and economic burden of stroke is therefore largely driven by its frequent occurrence in the elderly. The elderly have been strongly underrepresented in previous stroke trials and treatment guidelines have no recommendations specific to this important group. Elderly patients are at the highest risk of complications after stroke, such as infections, fever, and dysphagia. These complications are strongly and independently associated with a higher risk of death or dependency.We will perform a pragmatic, randomised, open clinical trial with blinded outcome assessment in at least 2500 patients with acute stroke aged 66 years or older, to assess whether pharmacological prevention of infections and fever, and early management of dysphagia, will reduce the risk of death, poor functional outcome, and poor quality of life, and lead to reductions in the costs of stroke care throughout Europe. Patients will be randomised using a factorial design to preventive treatment for 4 days with ceftriaxone, paracetamol, and/or metoclopramide, or to ‘standard care’ alone. The primary outcome is functional outcome at 3 months, assessed with the modified Rankin Scale (mRS), and analysed with ordinal logistic regression. The study will have 80% power to detect a statistically significant shift towards a favourable outcome, assuming a 5% absolute increase in the proportion of patients with a good outcome (mRS 0 to 2) in the intervention group, compared with controls. This simple, sa
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the specific objectives and expected outcomes for 'AIRFRAME ITD' in the context of a Horizon 2020 call.

assistant: **Objectives**

The Airframe ITD aims at re-thinking and developing the technologies as building blocks and the “solution space” on the level of the entire or holistic aircraft: pushing aerodynamics across new frontiers, combining and integrating new materials and structural techniques – and integrating innovative new controls and propulsion architectures with the airframe; and optimizing this against the challenges of weight, cost, life-cycle impact and durability.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'Identification of genes responsible for Immotile Cilia Syndrome (ICS)' goes beyond current state-of-the-art under Fourth Framework.

assistant: **Innovation**

Immotile cilia syndrome (ICS), also known as Primary Ciliary Dyskinesia, is a genetic disorder which is generally inherited in an autosomal recessive fashion. The incidence appears to be about 1/30,000. ICS affects ciliary movement, ranging from dysmotility or even complete immotility of spermatozoa as well as cilia in ciliated epithelia. This primary defect in ciliary function leads to recurrent pulmonary and upper respiratory tract infections, resulting often in bronchiectasis. Hearing problems, situs inversus and male infertility are associated symptoms. Most clinical manifestations begin in early childhood. Diagnostic tests, based on clinical symptoms, mucociliary clearance and ultrastructure, do not always give clear and satisfactory results. Treatment, which is currently purely symptomatic, involves dealing with complications in the upper and lower respiratory tracts. None of the gene(s) involved has been identified, although genetic heterogeneity is suspected on the basis of the complex architecture of cilia. Given the rarity of familial cases of ICS, a multinational collaboration is clearly necessary, since only this will allow the identification of a sufficiently large group of patients to overcome the problems associated with the genetic heterogeneity likely to be present. Furthermore, only the envisaged type of project will bring clinicians and scientists with complementary fields of expertise together. The partners of this project are convinced that improvement of diagnosis and eventually treatment of the disorder are crucially dependent on progress in identifying the genetic defects responsible. Finally, the proposed research is not only likely to be of value to patients and their families, but will also shed light on the large number of ciliary gene produc
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Seventh Framework proposal on 'Development of Vascular-Disrupting Lymphocyte Therapy for Tumours'.

assistant: **Innovation**

T cell engineering with chimeric antigen receptors has opened the door to effective immunotherapy. CARs are fusion genes encoding receptors whose extracellular domain comprises a single chain variable fragment (scFv) antibody that binds to a tumour surface epitope, while the intracellular domain comprises the signalling module of CD3ζ along with powerful costimulatory domains (e.g. CD28 and/or 4-1BB). CARs are a major breakthrough, since they allow bypassing HLA restrictions or loss, and they can incorporate potent costimulatory signals tailored to optimize T cell function. However, solid tumours present challenges, since they are often genetically unstable, and the tumour microenvironment impedes T cell function. The tumour vasculature is a much more stable and accessible target, and its disruption has catastrophic consequences for tumours. Nevertheless, the lack of affinity reagents has impeded progress in this area. The objectives of this proposal are to develop the first potent and safe tumour vascular-disrupting tumour immunotherapy using scFv’s and CARs uniquely available in my laboratory.I propose to use these innovative CARs to understand for the first time the molecular mechanisms underlying the interactions between anti-vascular CAR-T cells and tumour endothelium, and exploit them to maximize tumour vascular destruction. I also intend to employ innovative engineering approaches to minimize the chance of reactivity against normal vasculature. Lastly, I propose to manipulate the tumour damage mechanisms ensuing anti-vascular therapy, to maximize tumour rejection through immunomodulation. We are poised to elucidate critical interactions between tumour endothelium and anti-vascular T cells, and bring to bear cancer therapy of unparalleled power. The impact of this
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'Ready-to-use 3D Cell Cultures for early de-risking in drug development' to be submitted under Horizon 2020.

assistant: **Abstract**

StemTek is a global biopharmaceutical company with a clear stem cell focus in drug development for cancer treatment. Only about 10% of the candidate compounds progress successfully through clinical development. Many drugs fail during clinical trials, especially during phase III, which is the most expensive phase of clinical development, largely due to the lack of clinical efficacy and/or unacceptable toxicity.  StemTek is developing a solution to make cell based assays a commodity: easy to get, easy to buy, easy to use, and disposable, so we eliminate the need for large tissue culture facilities. This new solution is a ready-to-use 3D spheroid culture in standard 96 well plate format that allows customers to profile their pipeline of compounds for their effect on CSC populations using 3D culture models.  Thanks to the 3DCC, a business opportunity appears to develop a multi-million euro business capitalizing on the thriving interest from Pharma in finding novel biological testing systems based on 3D cell culture. Latest Markets&market report (2016) establishes that the global 3D cell culture market is expected to reach USD 1,345.2 M by 2021 from USD 466.8 M in 2016 at a CAGR of 23.6% (market growth). According to BCC research, from the seven different niches, “Reagents, media and sera” is precisely the most relevant (37.2 %).3DCC objectives are:• To produce tailor made kits to improve compatibility with different drug development programs, leading to a broad range of applications. • To use all the competitive advantages of CSC enriched 3D spheroid cultures in ready to use standard 96 well plate format. • The large-scale production of ready to use kits to be able to enter/supply the pharmaceutical industry to achieve economies of scale, and go from current 800 kits/year (
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'The critical shift to single-cell formats in functional analyses of living cells' goes beyond current state-of-the-art under Horizon Europe.

assistant: **Innovation**

The incredible potential of cell and immune therapy (CIT) is limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity. Single-cell functional resolution is essential to understand the full potential of immune cells. Current single-cell technologies are limited, low-throughput, high-cost and lack robustness, prohibitive for their implementation in CIT R&D, manufacturing and patient stratification. Samplix is developing Xplore, an all-in-one multiparameter single-cell analyser and sorter for screening, selection and expansion of immune cells based on functionality and potency. Xplore is a cost-effective solution that delivers higher throughput and sensitivity than current solutions, being compatible with CIT research workflows. Unlocking the full potential of CIT supports the faster and efficient development of new personalized therapies to treat serious diseases such as cancer, autoimmune diseases, and viral infections.


**Keywords:** Cell therapy,Microfluidics,Cell line development,Oncology,Immunology,Single-cell assays,Immune therapy,Multicolor Flow Cytometry
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Horizon 2020 proposal for the project 'Accelerating the Dissemination of Agluna(R), a clinically proven innovative silver ion based anti-microbial surface technology, from orthopaedics sector into the dental implant sector'.

assistant: **Objectives**

The project objective is to confirm the commercial application of Agluna(R), an innovative silver ion based anti-microbial surface technology, to dental implants. Agluna(R) has already demonstrated a significant reduction in the incidence of post-operative infection in clinical use within the EU limb salvage market, and is being actively commercialised within the wider global orthopaedic market.Implant related infections are associated with the formation of biofilm on the surface of implanted devices. This is a global problem with socio-economic costs recognised across a range of medical device sectors. The dental implant sector is actively searching for solutions to the problem of post-operative implant infection (peri-implantitis). With growing concern about antibiotic-resistant bacterial strains, the subsequent expected outcome following this project is for Agluna(R) to become commercialised in EU/global markets as a differentiated, cost effective and clinically proven technology utilising silver ions, a well-known biocide with very limited reported bacterial resistance.Phase 1 will confirm a business plan for successful commercialisation of Agluna(R) in the dental implant sector. We seek confirmation of:- the size and scope of the EU and global market opportunity in the dental sector;- competing approaches to prevention and control of post-operative infection in this sector;- market entry strategy taking account of EU and other international regulatory pathways;- investment requirements, time to market, and return on investment.Phase 1 is six months in duration; the principal deliverable is a fully substantiated business plan. This will provide the basis for Phase 2, in which Agluna(R) will be piloted on a dental implant product that is designed, manufactured and cl
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an executive summary for the EU project 'Theory and phenomenology of higgs-bosons at future high-energy collider experiments' (1994-1998) targeting Fourth Framework.

assistant: **Abstract**

Higgs-physics phenomenology is one of the most important topics in particle physics today. Understanding the origin of the masses of the known particles in the universe is likely to dominate European research in high energy physics for the forseeable future. This proposel suggests two parallel paths for a phenomenological investigation of the broken symmetry sector of the electroweak theory. One approach is concerned purely with Standard Model predictions for the Higgs-signal. In particular, the next to leading order contributions from polarized e+/- and pp beams to the helicity dependent production amplitudes for photon-photon and gluon-gluon fusion will be calculated. On the other hand it is necessary to also include models encompassing the Glashow-Weinberg-Salam model. For the presently most attractive of those, the minimal supersymmetric extension, the next to leading corrections to the decay branching ratios and production cross sections will be calculated. All the above mentioned contributions are needed to allow for unambiguous signal identification and background subtraction in the face of expected low production rates.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the 'Expected Impact' section for the project 'Fine Line Dispensing Process to apply Narrow Metal Contacts onto Solar Cells' (HighLine), addressing dissemination and exploitation.

assistant: **Impact**

HighLine Technology GmbH is a ISE spin-off from Fraunhofer Institute for Solar Energy Systems with exclusive IP rights to redefine the standard METALLIZATION process to apply the small contact lines made of silver onto Si-solar cells. With silver costs for metallization as the 2nd most expensive step in solar cell production, the PV industry is being responsible for >10% of the global silver demand. When it comes to cell efficiency, mainstream PERC cells have achieved max 23.5% efficiency and 0.05/kW cost limits. The promising next step in cell technology/efficiency with Heterojunction cells (HJT) requires more than double the silver laydown compromising industry adoption despite its efficiency benefits above 26%.   Designed to streamline metallization for today (PERC) and future (HJT) cells, HighLine FINE-LINE DISPENSING TECHNOLOGY enables cell producers the precise application of thinner contacts at 25% lower silver needs, 1% efficiency gains and 50% higher throughput.


**Keywords:** solar cell manufacturing
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Fifth Framework proposal for the project 'Metrology for anisotropic and lateral thermal transport in solids and thin films (METROTHERM)'.

assistant: **Objectives**

METROTHERM meets an urgent European industry need to support current developments in new materials with thermal metrology instrumentation. Affordable instrumentals are needed to map the lateral thermal transport in materials in multiple thin layer formats, which are unsuitable for measurement by existing methods. The project will leverage existing research expertise in Europe to deliver prototype instruments for exploitation by European companies within 12 months of completion. Thermal diffusivity mapping for a wide range of thermally conductive materials will be achieved. For low diffusivity samples thermally anisotropic, uniaxial electrically conductive adhesives (currently intended to replace lead-based solder) will be assessed for a consortium partner. Very high thermal conductivity materials being developed by an end user partner for electronic interconnection will have an efficient characterization method for the first time.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Genetic Analysis of Vascular Development in Zebrafish' under Seventh Framework.

assistant: **Concept**

The development of the vascular system is one of the earliest events in organogenesis. All other organs depend on a vascular supply for delivery of nutrients, oxygen and cellular and humoral factors, and for clearance of wastes.  Serious disruptions in the formation of the vascular network are lethal early in post-implantation, while the maintenance of vessel integrity and the control of vessel physiology have important consequences throughout embryonic and adult life. Research carried out over the past years has shed light into the different steps involved in the formation of the vascular system. Genetic evidence has highlighted the roles of many molecules that affect vasculogenesis, angiogenesis and lymphangiogenesis in a complex and tightly regulated manner.  Many of the signaling pathways implicated in vascular development are reactivated during disease states of angiogenesis or vessel regression, making a full understanding of the complexities of these pathways important for identifying new targets for therapeutic intervention during pathological situations such as severe tissue ischemia, coronary heart disease, lymphedema and tumor promoted angiogenesis and lymphangiogenesis.The objective of this proposal is to use the accessible zebrafish embryo, which has a well-described, stereotypical vertebrate vasculature, to identify and characterize novel players involved in the formation of blood and lymphatic vessels. The strength of our approach lies in our ability to combine unique in vivo assays, powerful genetic tools, and sophisticated long term imaging of living embryos. As most developmental processes are remarkably similar between zebrafish and humans, both in molecular aspects and function, these studies are likely to reveal conserved pathways regulating the dev
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'GRid enabled access to rich mEDIA content' goes beyond current state-of-the-art under Sixth Framework.

assistant: **Innovation**

Grid technology has achieved significant advances in the past few years with a plethora of prestigious organisations contributing to middleware that opens the horizons for new exploitation opportunities. However, this potential exploitation has not yet been seen to materialise in emerging applications. The use of Grid technology is still confined mainly within scientific applications, developed by scientific organisations, experts in Grid principles.The majority of IT application developing organisations is still afraid to delve into the use of Grid technologies, as they still sound new and remote to them. GREDIA will address this problem with the provision of a Grid application development platform. This will effectively be a tool which will provide high level support for the development of Grid business applications through a completely graphical user interface. The common characteristics of these business applications are the central concept of a Virtual Organisation and the demand for access and sharing of large quantities of distributed annotated numerical and multimedia content. Both desktop and mobile terminals will be addressed, with advances proposed in the Symbian Operating System relating to extensions that will facilitate mobile devices to exploit Grid technologies in a seamless way.The potential effects of the platform will be validated through two pilot applications servicing news and banking organisations, demonstrating secure access to distributed multimedia content in the first case and numerical annotated data in the second. The consortium includes key technology providers, established industrial players and leading academic institutions from 7 European countries along with a world re-known partner in the area of semantic Grid research from China.